



## **ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference**

May 29, 2024

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows:

Format: Fireside chat with analyst, Michael Yee and 1x1 Investor Meetings

Date: Wednesday, June 5, 2024

Time: 1:00 PM ET

Location: New York, NY

Webcast link: Available [here](#)

The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology's website at [Events](#) under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

### **About ALX Oncology**

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, evorpaccept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. To date, evorpaccept has been dosed in over 500 subjects and has demonstrated promising activity and favorable tolerability profile across a range of hematologic and solid malignancies in combination with various leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpaccept with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors.

Investor and Media Contact: Caitlyn Doherty Manager, Investor Relations and Corporate Communications, ALX Oncology  
[cdoherly@alxoncology.com](mailto:cdoherly@alxoncology.com) (650) 466-7125